背景:在过去的几十年中,药学服务(PC)发生了显着的发展,在广泛的背景下,更加关注患者的安全性和已证明的有效性。支持这项技术的许多证据来自美国,(PC)的评估和采用在全球范围内差异很大。
目的:本研究的目的是确定和评估17个中东国家的药学服务在各种药学方面的有效性。
方法:使用Arkesy和O\'Malley技术进行范围审查。它是使用PubMed/Medline进行的,Scopus,科克伦图书馆,SpringerLink,临床试验,和WebofScience等。VanTulder量表用于随机试验研究,而在非随机试验研究中使用黎明检查表和黑色检查表.对选定的研究进行了描述性和数值分析。符合条件的PC的范围,制药实施者,研究结果,和质量都是通过对研究的主题审查来确定的。
结果:在这项研究中发现了大约431,753条引文,在分析了271多篇全文文件后,发现129份出版物符合列入标准。研究设计多种多样,43个(33.3%)随机对照试验和86个(66.7%)n-RCTs。33项(25.6%)的研究发表于2020年。乔丹,沙特阿拉伯,土耳其是大多数研究的所在地(25.6%,16.3%,和11.6%)分别。37项研究(19.7%)涉及解决药物相关问题(DRP),而27例(14.4%)与提高生活质量(QOL)相关,23例(12.2%)与改善药物依从性相关.此外,研究显示,向患者提供的活动的平均评分每年都在提高。
结论:中东的研究继续提供证据支持药学服务对大多数研究测量的硬结果和软结果的积极影响。然而,很少有人关注已实施服务的价值。因此,必须严格评估在中东实施的药学服务的经济影响,并评估其可持续性。
Pharmaceutical care services (PCs) have evolved significantly over the last few decades, with a greater focus on patient\'s safety and proven effectiveness in a wide range of contexts. Many of the evidence supporting this technique comes from the United States, the evaluation and adoption of (PCs) which differ greatly across the globe.
The goal of this study was to identify and assess the efficacy of pharmaceutical care services in various pharmaceutical aspects throughout seventeen Middle Eastern nations.
The Arkesy and O\'Malley technique was used to conduct a scoping review. It was conducted using PubMed/Medline, Scopus, Cochrane Library, Springer Link, Clinical Trials, and Web of Science etc. The Van Tulder Scale was utilized in randomized trials research, whereas the dawn and black checklists were used in non-randomized trials research. A descriptive and numerical analysis of selected research was done. The scope of eligible PCs, pharmaceutical implementers, study outcomes, and quality were all identified by a thematic review of research.
There were about 431,753 citations found in this study, and 129 publications were found to be eligible for inclusion after analysing more than 271 full-text papers. The study design was varied, with 43 (33.3%) RCTs and 86 (66.7%) n-RCTs. Thirty-three (25.6%) of the studies were published in 2020. Jordan, Saudi Arabia, and Turkey were home to the majority of the studies (25.6%, 16.3%, and 11.6%) respectively. Thirty-seven studies (19.7%) were concerned with resolving drug related problems (DRPs), whereas 27 (14.4%) were concerned with increasing quality of life (QOL) and 23 (12.2%) with improving drug adherence. Additionally, the research revealed that the average ratings of the activities provided to patients improved every year.
Studies in the Middle East continue to provide evidence supporting the positive impact of pharmaceutical care services on both hard and soft outcomes measured in most studies. Yet there was rare focus on the value of the implemented services. Thus, rigorous evaluation of the economic impact of implemented pharmaceutical care services in the Middle East and assessment of their sustainability is must.